10x Genomics, Inc. Class A Common Stock (TXG) Technical Analysis
$68.59▲3.33%
Market is closed - opens 7 PM, 14 Sep 2026
Insights
- 10x Genomics Inc. Class A is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for 10x Genomics Inc. Class A stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, 10x Genomics Inc. Class A stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for 10x Genomics Inc. Class A stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 68.39 | Sell |
Stochastic | 90.15, 90.6 | Sell |
Ultimate Oscillator | 70.57 | Sell |
Stochastic Relative Strength Index | 63.59, 54.36 | Neutral |
Moving Average Convergence Divergence | 3.88, 3.99 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 63.94 | Buy |
20 | 62.89 | Buy |
50 | 53.2 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 64.88 | Buy |
20 | 62.19 | Buy |
50 | 54.1 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 63.69 | Buy |
20 | 62.75 | Buy |
50 | 52.75 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 67.23 | Sell |
20 | 67.54 | Buy |
50 | 65.72 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 67.37 | Buy |
20 | 67.24 | Sell |
50 | 68.97 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 71.72 |
Resistance L2 | 69.71 |
Resistance L1 | 68.05 |
Pivot Point | 66.04 |
Support L1 | 64.37 |
Support L2 | 62.36 |
Support L3 | 60.7 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.